Cheryl Alston, serving as a director at Globe Life Inc. (NASDAQ: GL), has reported the execution of share transactions totaling approximately $1.48 million on June 25, 2026, according to a recent Securities and Exchange Commission filing. The reported activity involved the acquisition of company common stock followed by immediate disposition, a process facilitated through the exercise of director stock options.
According to the filing, Alston acquired 14,017 shares of Globe Life common stock at a purchase price of $105.56 per share. This acquisition resulted in a total transaction value of $1,479,634. These shares were obtained through the exercise of Director Stock Options.
Immediately following the acquisition, Alston disposed of a total of 8,258 shares of common stock in multiple transactions. The sales occurred at prices ranging from $177.5608 to $180.57 per share. The cumulative value from these sales reached approximately $1,480,134. The sale prices came near Globe Life’s 52-week high of $181.15, as the stock has delivered a 44.6% return over the past year. According to InvestingPro analysis, the stock currently trades above its Fair Value, placing it on the most overvalued list.
Following these transactions, Cheryl Alston directly holds 16,621.037 shares of Globe Life common stock. This total includes 26.086 shares acquired through the company’s dividend reinvestment plan since her last report.
In other recent news, Globe Life Inc. reported its first-quarter 2026 earnings, showing a slight miss in earnings per share (EPS) compared to analyst forecasts. The company posted an EPS of $3.43, which fell short of the anticipated $3.48, representing a 1.44% negative surprise. Revenue, however, aligned with expectations, reaching $1.56 billion. Analyst firms have adjusted their price targets for Globe Life following these developments. TD Cowen raised its price target to $215, maintaining a Buy rating, highlighting the company’s attractive business model in the U.S. life insurance sector. Raymond James also increased its price target to $208, citing the company’s strong cash flow generation. BMO Capital raised its target to $150, noting a 4% increase in the midpoint of Globe Life’s excess cash flow guidance to $675 million. Truist Securities adjusted its price target to $185, reflecting a higher EPS outlook for 2026.